Derek Dobalian, MD
Gastroenterology · Long Beach, CANPI 1235225467
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Sunovion Pharmaceuticals Inc. accounts for 91.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $543 and has fallen 97.7% since, to $12 in 2023. That places this record below the midpoint for gastroenterology clinicians in CA, where the typical reported total is $1,790.
Across 201 payments — averaging $10.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- Gilead$98
- GSK$24
- Optinose US, Inc.$22
- Mylan Specialty L.p.$17
- Sumitomo Pharma America, Inc.$12
What the payments were for
- Food & beverage$2,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 193 | $1,849 |
| Gilead | 4 | $98 |
| GSK | 1 | $24 |
| Optinose US, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
How this compares
$2,022 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $7,015 |
| Pantoprazole Sodium | 108 | $3,067 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,407 |
| Humulin N KwikpenInsulin Nph Human Isophane | 27 | $1,290 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $722 |
| Novolog FlexpenInsulin Aspart | 20 | $679 |
| Phenytoin | 28 | $565 |
| Midodrine Hcl | 13 | $424 |
| Atorvastatin Calcium | 48 | $411 |
| Famotidine | 43 | $398 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $357 |
| Duloxetine Hcl | 14 | $329 |
| Oxycodone Hcl | 13 | $328 |
| Levetiracetam | 13 | $312 |
| Levothyroxine Sodium | 13 | $272 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Long Beach
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.